<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158703</url>
  </required_header>
  <id_info>
    <org_study_id>C.2009.120</org_study_id>
    <nct_id>NCT01158703</nct_id>
  </id_info>
  <brief_title>Aspirin and Plavix Following Coronary Artery Bypass Grafting</brief_title>
  <acronym>ASAP-CABG</acronym>
  <official_title>Aspirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Slim</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design of the study will be randomized, double blind trial, which will examine the
      effects of addition of clopidogrel to current guideline recommended background therapy on
      lowering the incidence of graft stenosis after coronary artery bypass grafting compared to
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate how well the combination of clopidogrel and aspirin
      lower the risk of clot forming in the bypass graft after open heart surgery. This combination
      has not yet been approved by the Food &amp; Drug Administration (FDA) for treating clots in the
      bypass graft. However, the FDA has not objected to its use to study its safety and
      effectiveness. This study will enroll approximately 150 total subjects all of which will be
      at Brooke Army Medical Center/Wilford Hall Medical Center. The study will be for 52 weeks
      from the day of surgery.

      After bypass surgery and inclusion criteria is met, subjects will be placed on aspirin 81 mg
      once daily and placebo once daily or aspirin 81 mg once daily and clopidogrel 75mg once daily
      to keep the bypass grafts open after surgery. There are no studies to date comparing the two
      study groups A CT scan of the heart will be done 2 weeks after surgery to see if the grafts
      are still open. At the end of the study, at 52-weeks mark, the subjects will undergo another
      heart scan to evaluate the bypass grafts and see if they are still open.

      Subjects will be seen on a 3 months basis until the end of the study, unless deemed necessary
      to return earlier for follow up. Subjects will undergo blood draw for complete blood count as
      part of the follow up visits to assess for safety while on the current study drug.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment and reduction in CT surgery support
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bleeding Between the Two Treatment Arms</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Major Adverse Cardiovascular Events With Combination Therapy</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of major adverse cardiovascular events(angina, any thrombotic events, and myocardial infarction) with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Angina Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of angina events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Myocardial Infarction Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of myocardial infarction events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Thrombotic Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of thrombotic events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Coronary Graft Patency</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin and clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>aspirin and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel 75mg daily by mouth daily for 12 months</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>sugar pill by mouth daily for 12 months</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>ASA, acetylsalicylic acid, Ecotrin, Fasprin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing coronary artery bypass grafting, with or without cardiopulmonary
             bypass

          -  Age â‰¥ 18

        Exclusion Criteria:

          -  Left ventricle ejection fraction &lt;30%

          -  Emergency surgery

          -  Valve surgery

          -  Redo CABG

          -  Postoperative cardiogenic shock for more than 48 hours

          -  Postoperative bleeding or cardiac tamponade

          -  More than 24 hours postoperative intubation course

          -  Requirement of postoperative anticoagulation

          -  Serum creatinine &gt;1.4

          -  Contraindication to use of postoperative coronary CT scan

          -  Allergy or contraindication to aspirin or clopidogrel

          -  Inability to provide informed consent

          -  Pregnant or breast feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad M Slim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Beck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Conner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <results_first_submitted>February 23, 2015</results_first_submitted>
  <results_first_submitted_qc>May 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2015</results_first_posted>
  <last_update_submitted>May 3, 2015</last_update_submitted>
  <last_update_submitted_qc>May 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Ahmad Slim</investigator_full_name>
    <investigator_title>director, cardiovascular research</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>coronary artery bypass graft</keyword>
  <keyword>Plavix</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clopidogrel</title>
          <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two active treatment groups</population>
      <group_list>
        <group group_id="B1">
          <title>Clopidogrel</title>
          <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="9.7"/>
                    <measurement group_id="B2" value="64.8" spread="10.2"/>
                    <measurement group_id="B3" value="66.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender distribution among groups</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.8" spread="10.7"/>
                    <measurement group_id="B2" value="115.4" spread="12.34"/>
                    <measurement group_id="B3" value="116.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="9.1"/>
                    <measurement group_id="B2" value="65.1" spread="7.3"/>
                    <measurement group_id="B3" value="67.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone</title>
        <description>Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo</description>
        <time_frame>52 weeks</time_frame>
        <population>Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone</title>
          <description>Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo</description>
          <population>Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo</population>
          <units>occluded grafts</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>grafts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Bleeding Between the Two Treatment Arms</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Bleeding Between the Two Treatment Arms</title>
          <units>BLEEDING EVENTS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Major Adverse Cardiovascular Events With Combination Therapy</title>
        <description>Number of major adverse cardiovascular events(angina, any thrombotic events, and myocardial infarction) with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
        <time_frame>52 weeks</time_frame>
        <population>above is the total number of all events reported</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Major Adverse Cardiovascular Events With Combination Therapy</title>
          <description>Number of major adverse cardiovascular events(angina, any thrombotic events, and myocardial infarction) with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
          <population>above is the total number of all events reported</population>
          <units>MACE Events over 52Wks</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>All events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Angina Events</title>
        <description>Number of angina events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
        <time_frame>52 weeks</time_frame>
        <population>above is the total number of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Angina Events</title>
          <description>Number of angina events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
          <population>above is the total number of participants</population>
          <units>Angina Events over 52Wks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Myocardial Infarction Events</title>
        <description>Number of myocardial infarction events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
        <time_frame>52 weeks</time_frame>
        <population>above is the total number of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Myocardial Infarction Events</title>
          <description>Number of myocardial infarction events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
          <population>above is the total number of participants</population>
          <units>MI Events over 52Wks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Thrombotic Events</title>
        <description>Number of thrombotic events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
        <time_frame>52 weeks</time_frame>
        <population>above is the total number of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel</title>
            <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Thrombotic Events</title>
          <description>Number of thrombotic events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
          <population>above is the total number of participants</population>
          <units>thrombotic Events over 52Wks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>52 weeks events of bleeding ( TIMI Major and Minor)</desc>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel</title>
          <description>aspirin and clopidogrel
clopidogrel: clopidogrel 75mg daily and aspirin 81mg by mouth daily for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>aspirin and placebo
sugar pill: sugar pill and aspirin 81mg by mouth daily for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>TIMI trials</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Number of Angina Events</sub_title>
                <description>Number of angina events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Number of Myocardial Infarction Events</sub_title>
                <description>Number of myocardial infarction events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Number of Thrombotic Events</sub_title>
                <description>Number of thrombotic events with combination therapy with aspirin and clopidogrel vs. aspirin alone</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study did not recruit enough patients due to strict exclusion criteria and low volume of consenting patients resulting in a sample size that was insufficient for power analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>AHMAD M. SLIM, MD, LTC, MC</name_or_title>
      <organization>BROOKE ARMY MEDICAL CENTER</organization>
      <phone>210-916-4717</phone>
      <email>AHMAD.SLIM@US.ARMY.MIL</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

